Clomacran: Difference between revisions
m url formatting |
consistent citation formatting |
||
(17 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Antipsychotic medication}} |
{{Short description|Antipsychotic medication}} |
||
{{cs1 config |name-list-style=vanc |display-authors=6}} |
|||
{{Infobox drug |
{{Infobox drug |
||
| Watchedfields = |
| Watchedfields = |
||
| verifiedrevid = |
| verifiedrevid = |
||
| INN = |
| INN = |
||
| IUPAC_name = 3-(2-chloro-9,10-dihydroacridin-9-yl)-N,N-dimethylpropan-1-amine |
| IUPAC_name = 3-(2-chloro-9,10-dihydroacridin-9-yl)-''N'',''N''-dimethylpropan-1-amine |
||
| drug_name = |
| drug_name = |
||
| synonyms = |
| synonyms = |
||
| type = |
| type = |
||
| image = |
| image = Clomacran no stereo.png |
||
| width = |
| width = |
||
| alt = |
| alt = |
||
Line 17: | Line 18: | ||
<!--Clinical data--> |
<!--Clinical data--> |
||
| pronounce = |
| pronounce = |
||
| tradename = Devryl, Olaxin,<ref name="chemicalbook">{{Cite web |title=Clomacran {{!}} 5310-55-4 |url=https://www.chemicalbook.com/ChemicalProductProperty_EN_CB61178346.htm |access-date=2023-08-25 |website=ChemicalBook |language=en}}</ref> Develar<ref name="Elks">{{Cite book |url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA297 |title=Dictionary of Drugs |date=1990 |publisher=Springer US |isbn=978-1-4757-2087-7 | |
| tradename = Devryl, Olaxin,<ref name="chemicalbook">{{Cite web |title=Clomacran {{!}} 5310-55-4 |url=https://www.chemicalbook.com/ChemicalProductProperty_EN_CB61178346.htm |access-date=2023-08-25 |website=ChemicalBook |language=en}}</ref> Develar<ref name="Elks">{{Cite book |url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA297 |title=Dictionary of Drugs |date=1990 |publisher=Springer US |isbn=978-1-4757-2087-7 | veditors = Elks J, Ganellin CR |location=Boston, MA |pages=297 |language=en |doi=10.1007/978-1-4757-2085-3 }}</ref><ref>{{Cite news |date=1986-11-05 |title=Substâncias e remédios sob controle |language=pt-br |trans-title=Substances and drugs under control |pages=14 |work=[[Jornal do Brasil]] |url=https://memoria.bn.br/pdf/030015/per030015_1986_00211.pdf |url-status=live |access-date=2023-08-08 |archive-url=https://web.archive.org/web/20230808230340/https://memoria.bn.br/pdf/030015/per030015_1986_00211.pdf |archive-date=2023-08-08}}</ref> |
||
| Drugs.com = |
| Drugs.com = |
||
| MedlinePlus = |
| MedlinePlus = |
||
Line 39: | Line 40: | ||
| legal_DE_comment = |
| legal_DE_comment = |
||
| legal_NZ = <!-- Class A, B, C --> |
| legal_NZ = <!-- Class A, B, C --> |
||
| legal_NZ_comment = |
| legal_NZ_comment = |
||
| legal_UK = |
|||
| legal_UK_comment = |
| legal_UK_comment = |
||
| legal_US = |
| legal_US = |
||
Line 48: | Line 48: | ||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> |
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> |
||
| legal_UN_comment = |
| legal_UN_comment = |
||
| |
| legal_UK= Withdrawn<ref name="Dixit">{{Cite journal | vauthors = Dixit N, Patel C, Bhavsar M, Patel S, Rawal R, Solanki H |date=2022-05-02 |title=Quantitative Structure-activity Relationship (QSAR) study of Liver Toxic Drugs |journal=International Association of Biologicals and Computational Digest |volume=1 |pages=63–71 |doi=10.56588/iabcd.v1i1.17 |eissn=2583-3995 |doi-access=free}}</ref> |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
Line 95: | Line 95: | ||
| specific_rotation = |
| specific_rotation = |
||
}} |
}} |
||
'''Clomacran''' is an [[antipsychotic drug]] of the [[acridine]] |
'''Clomacran''' is an [[antipsychotic drug]] of the dihydro[[acridine]] class, developed in the 1970s<ref name="Elks"/> by the pharmaceutical company [[Smith, Kline & French]] (now [[GlaxoSmithKline]]) under the brand names Devryl and Olaxin.<ref name="chemicalbook"/> |
||
It was withdrawn from market due to liver toxicity in 1982 |
It was used to treat schizophrenia in the 70s.<ref>{{cite journal | vauthors = Pecknold JC, Ban TA, Lehmann HE, Climan M | title = Clomacran in the treatment of schizophrenic patients: a comparison of two assessment methods | journal = International Journal of Clinical Pharmacology and Biopharmacy | volume = 11 | issue = 4 | pages = 299–303 | date = June 1975 | pmid = 1099021 }}</ref> It was withdrawn from the market in the UK, due to liver toxicity, in 1982.<ref name="Dixit" /><ref name="PubChem">{{Cite web |title=Clomacran |url= https://pubchem.ncbi.nlm.nih.gov/compound/21382 |access-date=2023-08-25 | work = PubChem |language=en | publisher = U.S. National Library of Medicine }}</ref><ref>{{Cite book |title=Mann's Pharmacovigilance |date=2014 |publisher=Wiley |isbn=978-0-470-67104-7 | veditors = Andrews EB, Moore N |edition=1st |language=en |doi=10.1002/9781118820186 }}</ref> |
||
==Synthesis== |
|||
[[File:Clomacran synthesis.svg|thumb|center|500px|Patents:<ref>Zirkle Charles L, {{US patent|3131190}} (1964 to Smith Kline French Lab).</ref><ref>E Anderson & H Graboyes, {{US patent|3781358}} (1973 to SmithKline Beecham Corp).</ref><ref>Elvin L Anderson & Harold Graboyes, {{US patent|3692834}} (1972 to Smith Kline and French Laboratories Ltd, GlaxoSmithKline LLC SmithKline Beecham Corp).</ref><ref>Elvin L Anderson & Harold Graboyes, {{US patent|3919312}} (1975 to SmithKline Beecham Corp).</ref>]] |
|||
The first step involves FGI of 3-chloro-N,N-dimethylpropylamine Fb: [109-54-6] ('''2''') into the Grignard reagent, i.e. (3-(Dimethylamino)propyl)magnesium chloride [19070-16-7] ([154034-91-0]). The Grignard reaction with 2-chloroacridone [7497-52-1] ('''1''') affords the tertiary carbinol ('''3'''). Dehydration by means of acid or simply heat gives the corresponding olefin ('''4'''). Catalytic reduction completes the synthesis of ('''5'''). |
|||
== References == |
== References == |
||
Line 106: | Line 111: | ||
[[Category:Typical antipsychotics]] |
[[Category:Typical antipsychotics]] |
||
[[Category:Acridines]] |
|||
[[Category:Chloroarenes]] |
|||
[[Category:Dimethylamino compounds]] |
|||
[[Category:Tertiary amines]] |
Latest revision as of 17:42, 25 June 2024
Clinical data | |
---|---|
Trade names | Devryl, Olaxin,[1] Develar[2][3] |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H21ClN2 |
Molar mass | 300.83 g·mol−1 |
3D model (JSmol) | |
Density | 1.120 g/cm3 [1] |
| |
|
Clomacran is an antipsychotic drug of the dihydroacridine class, developed in the 1970s[2] by the pharmaceutical company Smith, Kline & French (now GlaxoSmithKline) under the brand names Devryl and Olaxin.[1]
It was used to treat schizophrenia in the 70s.[6] It was withdrawn from the market in the UK, due to liver toxicity, in 1982.[4][7][8]
Synthesis[edit]
The first step involves FGI of 3-chloro-N,N-dimethylpropylamine Fb: [109-54-6] (2) into the Grignard reagent, i.e. (3-(Dimethylamino)propyl)magnesium chloride [19070-16-7] ([154034-91-0]). The Grignard reaction with 2-chloroacridone [7497-52-1] (1) affords the tertiary carbinol (3). Dehydration by means of acid or simply heat gives the corresponding olefin (4). Catalytic reduction completes the synthesis of (5).
References[edit]
- ^ a b c "Clomacran | 5310-55-4". ChemicalBook. Retrieved 2023-08-25.
- ^ a b Elks J, Ganellin CR, eds. (1990). Dictionary of Drugs. Boston, MA: Springer US. p. 297. doi:10.1007/978-1-4757-2085-3. ISBN 978-1-4757-2087-7.
- ^ "Substâncias e remédios sob controle" [Substances and drugs under control] (PDF). Jornal do Brasil (in Brazilian Portuguese). 1986-11-05. p. 14. Archived (PDF) from the original on 2023-08-08. Retrieved 2023-08-08.
- ^ a b Dixit N, Patel C, Bhavsar M, Patel S, Rawal R, Solanki H (2022-05-02). "Quantitative Structure-activity Relationship (QSAR) study of Liver Toxic Drugs". International Association of Biologicals and Computational Digest. 1: 63–71. doi:10.56588/iabcd.v1i1.17. eISSN 2583-3995.
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-03.
- ^ Pecknold JC, Ban TA, Lehmann HE, Climan M (June 1975). "Clomacran in the treatment of schizophrenic patients: a comparison of two assessment methods". International Journal of Clinical Pharmacology and Biopharmacy. 11 (4): 299–303. PMID 1099021.
- ^ "Clomacran". PubChem. U.S. National Library of Medicine. Retrieved 2023-08-25.
- ^ Andrews EB, Moore N, eds. (2014). Mann's Pharmacovigilance (1st ed.). Wiley. doi:10.1002/9781118820186. ISBN 978-0-470-67104-7.
- ^ Zirkle Charles L, U.S. patent 3,131,190 (1964 to Smith Kline French Lab).
- ^ E Anderson & H Graboyes, U.S. patent 3,781,358 (1973 to SmithKline Beecham Corp).
- ^ Elvin L Anderson & Harold Graboyes, U.S. patent 3,692,834 (1972 to Smith Kline and French Laboratories Ltd, GlaxoSmithKline LLC SmithKline Beecham Corp).
- ^ Elvin L Anderson & Harold Graboyes, U.S. patent 3,919,312 (1975 to SmithKline Beecham Corp).